Figure 1

Figure 1. From: Risk Factors for Detectable HIV-1 RNA at Delivery among Women Receiving Highly Active Antiretroviral Therapy in the Women and Infants Transmission Study.

Of these, 364 (58%) were HAART-experienced prior to pregnancy and 266 (42%) were HAART-naïve prior to pregnancy. A comparison of enrollment characteristics by history of HAART exposure is shown in . There were significant differences between HAART-experienced and HAART-naïve women in age, insurance status, parity, and time since HIV diagnosis (median of 5 years in the HAART-experienced group versus 6 months in the HAART-naïve group). The median CD4+ cell count overall was 435 cells/μl (IQR 294, 640), however, women who were naïve to HAART prior to pregnancy were more likely to have a first CD4+ cell count measurement >200 cells/μl (95% vs. 83%, p<0.001) and lower CDC class (73% vs. 54% Class A, p<0.001). Among both HAART-experienced and HAART-naïve women, 53% had a detectable HIV-1 RNA at first study measurement in pregnancy. There was a significant difference between HAART-experienced and HAART-naïve women in the proportion of women using the different types of regimens (p<0.001, ). This primarily reflected a higher proportion of HAART-experienced compared to HAART-naïve women who received a boosted PI-regimen. We also examined the distribution of women by year of study enrollment (). The proportion of women with detectable HIV-1 RNA at enrollment varied significantly by calendar year of enrollment, reflecting declining trends over time, both among women who were HAART-experienced prior to pregnancy (p<0.001) and among women who were naïve prior to pregnancy (p<0.001).

Ingrid T. Katz, et al. J Acquir Immune Defic Syndr. ;54(1):27-34.

Supplemental Content

Filter your results:

Search details

See more...

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk